3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Interventions
Gemcitabine
6
Pemetrexed
3
Cisplatin
3
Carboplatin
3
atezolizumab
2
Trastuzumab
2
Sugammadex
2
Paclitaxel
2
Neostigmine
2
vinflunine
1
poly ICLC
1
pembrolizumab
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
delta 24-sterol reductase
1
daratumumab
1
avelumab
1
apatorsen
1
abemaciclib
1
Water
1
Thalidomide
1
Surveys and Questionnaires
1
Saline Solution
1
Rocuronium
1
Nephroureterectomy
1
Nephrectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urologic Neoplasms
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts